Form 4: RAPT Therapeutics Chief Medical Officer Amends Stock Options
SEC Form 4
RAPT Therapeutics' Chief Medical Officer, William Ho, amended several employee stock options on November 13, 2024, resulting in the cancellation of old options and the grant of new replacement options.
Summary
- On November 13, 2024, RAPT Therapeutics' Chief Medical Officer, William Ho, amended multiple employee stock options.
- These amendments involved the cancellation of existing options and the grant of new replacement options with varying exercise prices and expiration dates.
- The new options have exercise prices of $1.57 per share, while the cancelled options had exercise prices ranging from $12 to $44.66.
- The options vest monthly over a four-year period, with vesting start dates ranging from January 1, 2020, to January 1, 2024.
- The total number of shares underlying the new options is 268,807.
Sentiment
Score: 6
Explanation: The document is neutral in sentiment, as it primarily reports a routine transaction of stock option amendments. There are no indications of positive or negative news regarding the company's performance.
Positives
- The new options have a lower exercise price of $1.57 per share, which could be beneficial for the employee if the stock price increases.
- The vesting schedule of 1/48th per month provides a steady incentive for the employee.
Risks
- The value of the options is dependent on the future performance of RAPT Therapeutics' stock price.
- The options have expiration dates, meaning they will become worthless if not exercised by the expiration date.
Industry Context
Stock option grants and amendments are a common practice in the biotechnology industry to incentivize and retain key personnel.
Comparison to Industry Standards
- Stock option grants are a standard form of compensation for executives in the biotech industry.
- The vesting schedule of 1/48th per month is a typical vesting schedule for stock options.
- The exercise price of $1.57 is likely reflective of the current market price of the stock at the time of the amendment.
Stakeholder Impact
- The stock option amendments may have a minor positive impact on employee morale.
- The amendments do not have a direct impact on shareholders, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 10/30/2019 | Original grant date of the first amended option. |
| 01/30/2020 | Original grant date of the second amended option. |
| 01/01/2020 | Vesting start date for the second amended option. |
| 01/28/2021 | Original grant date of the third amended option. |
| 01/01/2021 | Vesting start date for the third amended option. |
| 01/28/2022 | Original grant date of the fourth amended option. |
| 01/01/2022 | Vesting start date for the fourth amended option. |
| 01/31/2023 | Original grant date of the fifth amended option. |
| 01/01/2023 | Vesting start date for the fifth amended option. |
| 01/31/2024 | Original grant date of the sixth amended option. |
| 01/01/2024 | Vesting start date for the sixth amended option. |
| 11/13/2024 | Date of the stock option amendments. |
| 11/15/2024 | Date of the filing. |
| 10/29/2029 | Expiration date of the first two amended options. |
| 01/29/2030 | Expiration date of the second two amended options. |
| 01/27/2031 | Expiration date of the third two amended options. |
| 01/27/2032 | Expiration date of the fourth two amended options. |
| 01/30/2033 | Expiration date of the fifth two amended options. |
| 01/30/2034 | Expiration date of the sixth two amended options. |
Keywords
stock options, employee stock options, RAPT Therapeutics, William Ho, option amendment, executive compensation, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.